PLEASANTON, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, today announced that it will report its operating results for the fourth quarter and full year 2006 on Tuesday, January 31.
The company will hold a conference call to discuss its financial results and operating activities to all interested parties at 1:30 p.m., Pacific Standard Time (4:30 p.m., Eastern Standard Time), Tuesday, January 31, hosted by D. Keith Grossman, president and chief executive officer, and Cynthia Lucchese, senior vice president and chief financial officer.
The teleconference call can be accessed by calling 719-457-2727, passcode 4776841. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available via the Internet at http://phx.corporate- ir.net/phoenix.zhtml?p=iroleventDetails&c=95989&eventID=1194434 or at http://www.thoratec.com .
A replay of the conference call will be available through Tuesday, February 14, via http://www.thoratec.com , or by telephone at 719-457-0820, passcode 4776841.
Thoratec Corporation is a world leader in hemodynamic restoration therapy -- developing products to treat cardiovascular disease. The company’s product line also includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (left ventricular assist system) with more than 10,000 devices implanted in patients suffering from heart failure. Thoratec’s HeartMate XVE LVAS is the first, and to date, only FDA-approved device for Destination Therapy, or the permanent support of late-stage heart failure patients who are not eligible for heart transplantation. Thoratec’s product line also includes the Vectra(R) vascular access graft (VAG) for patients undergoing hemodialysis. Additionally, its International Technidyne Corporation (ITC) division supplies blood coagulation testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s websites at http://www.thoratec.com or http://www.itcmed.com .
Thoratec Corporation
CONTACT: investors, Cynthia Lucchese, Senior Vice President, ChiefFinancial Officer of Thoratec Corporation, +1-925-847-8600; or Neal Rosenof Kalt Rosen & Company, +1-415-397-2686, for Thoratec Corporation; orJennifer Chan of FischerHealth, Inc., +1-310-577-7870, ext. 164, orjchan@fischerhealth.com, for Thoratec Corporation
Web site: http://www.thoratec.com/
